There were 2,043 press releases posted in the last 24 hours and 353,370 in the last 365 days.

Joint Statement of the FLCCC Alliance and BiRD Group on Retraction of Early Research on Ivermectin

The Front Line COVID-19 Critical Care Alliance Logo

The Front Line COVID-19 Critical Care Alliance

A reexamination of the data without the earlier research continues to prove that ivermectin is effective in preventing and treating COVID-19

This is not just about correcting facts but about people’s lives.”
— Dr. Tess Lawrie
WASHINGTON, DC, USA, July 16, 2021 / -- The Front Line COVID-19 Critical Care Alliance (FLCCC), a group of highly published, world-renowned critical care physicians and scholars, and the British Ivermectin Recommendation Development Group (BIRD), a U.K. based group of medical and scientific experts from over 15 countries, are concerned over the misrepresentation of science in the recent article published in the Guardian regarding the withdrawal of Professor Emeritus Ahmed Elgazzar’s study into ivermectin that was first posted December 16, 2020.

Contrary to the voices quoted in the article, there is no scientific basis to state that the removal of one study from meta-analyses would ‘reverse results.’ Worryingly, this article’s insinuation is reported as if it is fact.

According to the most recent analyses by BIRD, excluding the Elgazzar data from the cited meta-analyses by Bryant and Hill does not change the conclusions of these reviews, with the findings still clearly favouring ivermectin for both prevention and treatment.

This article raise questions of journalistic integrity and we invite the Guardian to make appropriate corrections to the reporting and properly check the veracity of their claims.

“This is not just about correcting facts but about people’s lives,” said Dr. Tess Lawrie, director of the Evidence-Based Medicine Consultancy and organizer of the BIRD group. “Ivermectin is already in use around the world and can reach the poorest people long before other expensive COVID treatments will ever get to them. Ivermectin has an ever-increasing evidence base that shows that it works –even the prestigious Institute Pasteur in France has confirmed that the evidence is sound.”

“When we examine the extensive evidence on ivermectin as a treatment for COVID-19 without this latest study, we still see a significant reduction in the spread of COVID-19 as well as a reduction in hospitalizations and death,” said Dr. Pierre Kory, president and chief medical officer of the FLCCC. “All science needs to be scrutinized. As some of the most published researchers in our fields, we are used to having our work examined by others. I hope that Dr. Elgazzar’s work will be impartially judged and any errors that might be found are corrected.”

About the Front Line COVID-19 Critical Care Alliance
The FLCCC Alliance was organized in March 2020 by a group of highly published, world renowned Critical Care physician/scholars – with the academic support of allied physicians from around the world – to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. Their MATH+ Hospital Treatment Protocol, introduced in March 2020, has saved thousands of patients who were critically ill with COVID-19. Now, the FLCCC’s new I-Mask+ Prophylaxis and Early At-Home Outpatient Treatment Protocol with Ivermectin has been released – and is a potential solution to the global pandemic.
For more information:

About the BIRD group
Convened by The Evidenced-Based Medical Consultancy (E-BMC) in Bath, United Kingdom, the BIRD meeting was assembled according to the World Health Organization Handbook of Guideline Development to review the latest science on the safety and efficacy of Ivermectin for the treatment and prevention of COVID-19. The expert panel included medical and scientific experts from 16 countries, including Argentina, Australia, Belgium, Canada, France, Hungary, India, Ireland, Japan, Peru, Nigeria, South Africa, Philippines, United States, United Kingdom


Joyce Kamen
FLCCC Alliance
+1 513-486-4696
email us here
Visit us on social media: